US 12,435,080 B2
sGC stimulators
Glen Robert Rennie, Somerville, MA (US); Timothy Claude Barden, Gibsonia, PA (US); Thomas Wai-Ho Lee, Lexington, MA (US); Rajesh R. Iyengar, West Newton, MA (US); Takashi Nakai, Newton, MA (US); Ara Mermerian, Waltham, MA (US); Lei Jia, San Diego, CA (US); Karthik Iyer, Cambridge, MA (US); G-Yoon Jamie Im, Cambridge, MA (US); Paul Allan Renhowe, Sudbury, MA (US); Joon Jung, Newton, MA (US); Peter Germano, Newton, MA (US); and Kim Tang, Belmont, MA (US)
Assigned to Tisento Therapeutics Inc., Cambridge, MA (US)
Filed by Tisento Therapeutics Inc., Cambridge, MA (US)
Filed on Sep. 27, 2021, as Appl. No. 17/485,858.
Application 17/485,858 is a continuation of application No. 16/348,377, granted, now 11,180,493, previously published as PCT/US2017/060305, filed on Nov. 7, 2017.
Claims priority of provisional application 62/419,086, filed on Nov. 8, 2016.
Prior Publication US 2022/0017515 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 487/04 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 487/04 (2013.01)] 6 Claims
 
1. A compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from those listed in the table below:
 
 
 
 

OG Complex Work Unit Chemistry
 I-5
 
 
 
 

OG Complex Work Unit Chemistry
 I-31
 
 
 
 

OG Complex Work Unit Chemistry
 I-62
 
 
 
 

OG Complex Work Unit Chemistry
 I-101
 
 
 
 

OG Complex Work Unit Chemistry
 I-105